JUBILANT PREMIER LEAGUE 2024
The much awaited Jubilant Premier League 2024 concluded with high-octane energy from the participating teams. The tournament unfolded nail-biting moments and witnessed many record-breaking events. The sportsmanship and the incredible performances kept the spirits of Jubilant high taking the excitement to a different level.
This year we saw presence of 12 teams fighting for the Jubilant Premier League 2024 trophy.
In the finale, Biosys Fighters retained the trophy for the fifth time defeating Finance Fighters in a fierce battle. The captain of Biosys Fighters, Dr Anuj Rathi lifted the fifth trophy in the post-match presentation ceremony that was given by Jubilant Ingrevia Limited’s MD and CEO, Mr. Deepak Jain. Krishan Bhati bagged the Player of the Match trophy while Pradnyavant Bhalerao was declared the Best Bowler of the Tournament (10 wickets). Binny Thomas from SCM Raiders took home the trophy of Best Batter and Player of the Tournament for his outstanding performance of 220 runs, 8 wickets, 1 catch and 3 dismissals. The individual trophies were handed over by Mr. Prasad Vasant Joglekar – President, Supply Chain; Mr. Vijay Kumar Srivastava – President, Operations; Mr. Gaurav Kushwaha - Chief Digital and Information Officer.
JUBILANT WOMEN'S PREMIER LEAGUE 2024
Total 4 teams battled out with each other and unfolded some incredible cricketing performances with the only aim to claim the Jubilant Women's Premier League 2024 trophy.
Dabangg Warriors and Mystic Maidens progressed to the finals while Rainbow Strikers and Jubiladies were knocked out of the tournament in the semi-finals.
In the finale, Mystic Maidens displayed phenomenal team effort to clinch the winner trophy of Jubilant Women's Premier League 2024.
Puja Rana was declared the Player of the Match. Reshma Inamdar (Mystic Maidens) was declared the Best Batter of the tournament while Ananya Choudhury (Dabangg Warriors) won the Best Bowler of the tournament trophy.
Ursilan Qadir from Dabangg Warriors was announced the Player of the Tournament for her all-round performance of 42 runs and 2 wickets.
JUBILANT VETERANS CUP 2024
The much talked about Veterans Cup 2024 was nothing less than a spectacle that witnessed the leaders from senior management giving it all to clinch the trophy.
Team Titans VS Team Giants battled it out in the exhibition match where defending champions Titans gave it all to defend the trophy in the exhibition match.
The noteworthy performances from Titans came from Anil Srivastava, Deepti Ranjan Dash, Yuvraj B which helped them putting up the target of 107 for the Giants.
Giants responded with careful and steady batting by Deepak Jain, Gaurav Kushwaha and Prasad Joglekar in spite of wickets falling in quick succession. They fought it out but fell short from reaching the target score and they could put up only 100 runs in 12 overs on the score board.
Titans’ captain Anil Srivastava bagged the Player of the Match award (36 runs from 29 balls).
We saw the sportsmanship spirits coming from both the teams that made this match more special.
JUBILANT PHARMOVA LIMITED - Q3 FY24 & 9M FY24 FINANCIAL RESULTS
The Board of Jubilant Pharmova Limited met to approve financial result for the quarter ended Dec. 31, 2023. The highlights were as follows:
Total income grew by 10% to Rs. 1,713 Cr. on the back of growth in Ruby-Fill® and new product sales in radiopharmaceuticals, volume growth in radiopharmacies, continued growth momentum in Allergy Immunotherapy business, growth in CDMO Sterile Injectables and growth in other income.
EBITDA grew by 63% to Rs. 254 Cr. on YoY basis due to improved performance across segments led by Radiopharma, Allergy Immunotherapy, CRDMO and Generics. In line with the management’s guidance, Radiopharmacy business has pivoted to profitability in FY24. The generics business is also moving towards profitability. Q3’FY24 PAT increased YoY to Rs. 66 Cr. on improved operating performance and increased profit share from an associate, Sofie Biosciences Inc.
For more information please click here.
JUBILANT PHARMOVA’S WHOLLY OWNED SUBSIDIARY TO SELL ITS ENTIRE 25.8% STAKE IN SOFIE BIOSCIENCES INC., USA
Jubilant Pharma Limited, Singapore (‘JPL’), a wholly owned subsidiary, in Nov’2020 invested USD 25 Million in Sofie Biosciences Inc., USA (‘Sofie’) and currently holds 25.8% stake.
Sofie is engaged in developing and delivering molecular diagnostics and therapeutics (theranostics). It has radiopharmaceutical production and distribution network, mature contract manufacturing services and high value theranostic intellectual property. Sofie has now entered into a definitive merger agreement with certain private equity funds managed by [Trilantic Capital Partners, North America (‘Trilantic North America’)], a US private equity firm. The merger transaction is expected to close by 30th June 2024, subject to customary conditions and regulatory approvals. Consequently, JPL plans to sell its entire 25.8% equity stake in Sofie for aggregate proceeds of about USD 139.43 Million, including certain preferred returns. Of this, USD 113.63 Million (subject to certain customary adjustments at closing) is expected to be received upon completion of the merger while receipt of balance sum of USD 25.8 Million is contingent upon achievement of certain future milestones. JPL plans to use these proceeds to reduce leverage and for capex and other corporate purposes.